Two negative controls for the interaction were DLC1 deletion mutant 929–957 and a previously characterized DLC1 cancer-associated point mutant E996K, whose mutation lies just downstream from the amino acids in the deletion mutant. The gene discussed is DLC1; the disease is cancer.